CVS Health Corp vs JPMorgan Diversified Return International Eqty ETF — how do they compare? CVS Health Corp trades at $86.68 (market cap $112.29B), while JPMorgan Diversified Return International Eqty ETF trades at $73.01 (market cap $378.77M). The key difference: CVS Health Corp is far larger — about 296.5× JPMorgan Diversified Return International Eqty ETF's market cap, and CVS Health Corp pays a 3.03% dividend while JPMorgan Diversified Return International Eqty ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and JPMorgan Diversified Return International Eqty ETF for 120 Days on average.
| CVS | JPIN | |
|---|---|---|
Market Cap | $112.29B | $378.77M |
Volume | 7,763,676 | 13,861 |
Sector | Health | — |
52-Week High | $110.60 | $77.80 |
52-Week Low | $70.08 | $64.96 |
Typical Hold Time | 83 Days | 120 Days |
Enterprise Value | $174.64B | — |
Dividend Yield | 3.03% | — |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.
The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.
JPIN trades at $73.01, showing minimal daily movement with a 0.1% gain. Technical indicators are predominantly bearish, with moving averages and oscillators signaling selling pressure, though RSI levels suggest potential oversold conditions. The ETF, designed for international equity exposure, lacks current fundamental data for valuation ratios and profitability metrics.
The outlook remains cautious due to strong bearish technical signals and absence of recent financial updates. Key risks include market volatility and reliance on international equities. Investors should await earnings reports for fundamental clarity, as current data is insufficient to assess valuation or growth prospects.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →